Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.

Surgical oncology - 1 Sept 2020

Barrington David A, Felix Ashley S, Owda Rieham, Suarez Adrian A, Cohen David W, Senter Leigha, Copeland Larry J, Fowler Jeffrey M, Backes Floor J, Cohn David E, Bixel Kristin L, O'Malley David M, Salani Ritu, Cosgrove Casey M

Abstract excerpt

OBJECTIVE: A pathologic chemotherapy response score (CRS) is used to grade ovarian cancer response to neoadjuvant chemotherapy (NACT). We evaluated the prognostic significance of the CRS in a single institution cohort. METHODS: A retrospective review of all consecutive epithelial ovarian cancer patients undergoing interval debulking surgery (IDS) after NACT from 2016 to 2017 were included. Clinical, pathologic,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ovarian Epithelial

Share to Chemotherapy, Adjuvant

Share to Follow-Up Studies

Share to Genetic Testing

Share to Neoadjuvant Therapy

Share to Survival Rate

Source

Identifiers

PMID: 32891351
DOI: 10.1016/j.suronc.2020.03.001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.PMID 32891351Read ↗

TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.Semantic proximity Read ↗

Germline BRCA, Chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancerSemantic proximity Read ↗

Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy.Semantic proximity Read ↗

Ovarian Cancer: Many Diseases Under One Name.Semantic proximity Read ↗

Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and TreatmentSemantic proximity Read ↗

Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratificationSemantic proximity Read ↗

Molecular and phenotypic characteristics influencing the degree of cytoreduction in high-grade serous ovarian carcinomas.Semantic proximity Read ↗

Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.Semantic proximity Read ↗

Clinicogenomic Landscape of Histologic Subtypes in Ovarian Cancer: Real-World Evidence From a Japanese Nationwide Cohort.Semantic proximity Read ↗

Clinicopathological characterization of a real-world multicenter cohort of endometrioid ovarian carcinoma: Analysis of the French national ESME-Unicancer database.Semantic proximity Read ↗

Prediction of chemo-response in serous ovarian cancerSemantic proximity Read ↗

Association of Copy Number Variation Signature and Survival in Patients With Serous Ovarian CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.